CO2022011944A2 - Moléculas de unión a antígeno contra alppl2 y/o alpp y usos de las mismas - Google Patents

Moléculas de unión a antígeno contra alppl2 y/o alpp y usos de las mismas

Info

Publication number
CO2022011944A2
CO2022011944A2 CONC2022/0011944A CO2022011944A CO2022011944A2 CO 2022011944 A2 CO2022011944 A2 CO 2022011944A2 CO 2022011944 A CO2022011944 A CO 2022011944A CO 2022011944 A2 CO2022011944 A2 CO 2022011944A2
Authority
CO
Colombia
Prior art keywords
alppl2
binding molecules
alpp
antigen binding
molecules against
Prior art date
Application number
CONC2022/0011944A
Other languages
English (en)
Spanish (es)
Inventor
William Sun
Boon Ooi Patrick Tan
Huajing Wang
Thai Leong Yap
Shin Yee Hong
Cheng-I Wang
Ching-Wen Huang
Shuet Theng Lee
Kah Fei Wan
Jian Duan Johnathan Ng
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of CO2022011944A2 publication Critical patent/CO2022011944A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CONC2022/0011944A 2020-02-07 2022-08-23 Moléculas de unión a antígeno contra alppl2 y/o alpp y usos de las mismas CO2022011944A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10202001139U 2020-02-07
PCT/SG2021/050061 WO2021158178A1 (en) 2020-02-07 2021-02-05 Antigen-binding molecules against alppl2 and/or alpp and uses thereof

Publications (1)

Publication Number Publication Date
CO2022011944A2 true CO2022011944A2 (es) 2022-08-30

Family

ID=77199411

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0011944A CO2022011944A2 (es) 2020-02-07 2022-08-23 Moléculas de unión a antígeno contra alppl2 y/o alpp y usos de las mismas

Country Status (19)

Country Link
US (1) US20230080224A1 (cg-RX-API-DMAC7.html)
EP (1) EP4100443A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023512827A (cg-RX-API-DMAC7.html)
KR (1) KR20220139930A (cg-RX-API-DMAC7.html)
CN (1) CN115380050B (cg-RX-API-DMAC7.html)
AU (1) AU2021217919A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022015540A2 (cg-RX-API-DMAC7.html)
CA (1) CA3170141A1 (cg-RX-API-DMAC7.html)
CL (3) CL2022002114A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022011944A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220441A (cg-RX-API-DMAC7.html)
DO (2) DOP2022000159A (cg-RX-API-DMAC7.html)
EC (1) ECSP22061867A (cg-RX-API-DMAC7.html)
IL (1) IL295291A (cg-RX-API-DMAC7.html)
JO (1) JOP20220175A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022009709A (cg-RX-API-DMAC7.html)
PE (1) PE20221781A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552038A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021158178A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240083182A (ko) * 2021-09-22 2024-06-11 더 리전츠 오브 더 유니버시티 오브 캘리포니아 종양 특이적 이중특이성 면역세포 인게이저
CN120882866A (zh) * 2022-12-21 2025-10-31 阿尔麦克探索有限公司 Alpp特异性变体抗原结合分子
WO2026149352A1 (zh) * 2025-01-07 2026-07-16 北京泰德制药股份有限公司 一种抗alpp和/或alppl2抗体及其应用
WO2026156021A1 (en) 2025-01-16 2026-07-23 Merck Sharp & Dohme Llc Bispecific antibody constructs that bind alpp/alppl2 and cd3

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
KR20180005753A (ko) * 2008-06-25 2018-01-16 에스바테크 - 어 노바티스 컴파니 엘엘씨 Vegf를 억제하는 안정하고 가용성인 항체
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
EP3383920B1 (en) * 2015-11-30 2024-01-10 The Regents of the University of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
JP2019131471A (ja) * 2016-05-27 2019-08-08 国立大学法人 東京大学 抗TGF−beta3抗体およびその使用
CN108088997B (zh) * 2016-11-21 2020-03-17 同济大学 利用细胞表面分子标志物鉴定人类原态多能性的方法

Also Published As

Publication number Publication date
CN115380050B (zh) 2026-07-03
AU2021217919A1 (en) 2022-09-29
PH12022552038A1 (en) 2023-11-29
BR112022015540A2 (pt) 2022-12-27
JP2023512827A (ja) 2023-03-29
CL2022002114A1 (es) 2023-03-03
ECSP22061867A (es) 2022-09-30
CL2024002074A1 (es) 2025-01-10
CR20220441A (es) 2022-12-14
JOP20220175A1 (ar) 2022-07-28
EP4100443A4 (en) 2024-05-15
IL295291A (en) 2022-10-01
CL2024002073A1 (es) 2025-01-10
KR20220139930A (ko) 2022-10-17
DOP2025000135A (es) 2025-07-15
CA3170141A1 (en) 2021-08-12
JP2026027248A (ja) 2026-02-18
CN115380050A (zh) 2022-11-22
US20230080224A1 (en) 2023-03-16
DOP2022000159A (es) 2022-09-30
MX2022009709A (es) 2022-09-09
PE20221781A1 (es) 2022-11-16
WO2021158178A1 (en) 2021-08-12
EP4100443A1 (en) 2022-12-14

Similar Documents

Publication Publication Date Title
ECSP22061867A (es) Moléculas de unión a antígeno contra alppl2 y/o alpp y usos de las mismas
CL2024001607A1 (es) Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t.
MX2022002977A (es) Tratamiento y prevencion del cancer usando moleculas de union a antigeno her3.
CO2021009693A2 (es) Proteínas de unión a antígeno del receptor gamma anti-il2
PE20211786A1 (es) Anticuerpos humanizados contra c-kit
BR112021023026A2 (pt) Moléculas de ligação biespecíficas anti-ror1/anti-cd3
MX2021002690A (es) Anticuerpos anti-avb8 y composiciones y usos de los mismos.
CO2019007823A2 (es) Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo
MX2018014456A (es) Anticuerpos contra alfa-sinucleina y sus usos.
CR20170124A (es) Agente terapeutico que induce citotoxicidad
MX2018011035A (es) Anticuerpos-anti-mica.
UA103916C2 (xx) Антитіло проти dkk-1$антитело против dkk-1
MX2025003354A (es) Anticuerpos que se unen a 5t4
MX2021016098A (es) Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas.
BRPI0912570B8 (pt) anticorpo anti-ifn-alfa humanizado, ou um fragmento de ligação ao antígeno do mesmo, composição terapêutica e seus usos
CY1126032T1 (el) Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap
AR116897A1 (es) Métodos para tratar el cáncer con una combinación de un anticuerpo anti-vegf y un conjugado anticuerpo-fármaco anti-factor tisular
MX2023001707A (es) Composiciones y métodos para el tratamiento de enfermedades autoinmunes y cánceres por direccionamiento al miembro 8 de la superfamilia de inmunoglobulinas.
MX2021003263A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.
MX2025000437A (es) Inmunoconjugados de epcam y usos de estos
JOP20240132A1 (ar) أجسام مضادة لـ c3 وشظايا ارتباط بمولد الضد منها واستخداماتها لعلاج العين أو الأمراض العينية
MX2022004312A (es) Anticuerpos humanizados anti-receptor tipo quimiocina 1 y sus aplicaciones terapeuticas.
CO2025002301A2 (es) Anticuerpos anti-ccr8 y métodos de uso
CL2025001398A1 (es) Anticuerpos anti-cd48, conjugados de anticuerpo-fármaco, y usos de los mismos
ECSP23058549A (es) Anticuerpos monoclonales anti-gprc5d y usos de los mismos